Corient Private Wealth LLC Has $346,000 Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

Corient Private Wealth LLC lessened its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 61.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,233 shares of the medical instruments supplier’s stock after selling 3,578 shares during the quarter. Corient Private Wealth LLC’s holdings in ICU Medical were worth $346,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in ICU Medical by 10.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock valued at $54,868,000 after buying an additional 27,927 shares during the period. Citigroup Inc. boosted its position in shares of ICU Medical by 100.4% during the 3rd quarter. Citigroup Inc. now owns 28,965 shares of the medical instruments supplier’s stock valued at $5,278,000 after acquiring an additional 14,512 shares in the last quarter. Cerity Partners LLC increased its stake in ICU Medical by 33.2% in the third quarter. Cerity Partners LLC now owns 9,846 shares of the medical instruments supplier’s stock valued at $1,794,000 after acquiring an additional 2,454 shares during the period. FMR LLC raised its position in ICU Medical by 2,676.6% in the third quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock worth $18,968,000 after purchasing an additional 100,345 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in ICU Medical by 16.5% during the third quarter. BNP Paribas Financial Markets now owns 6,997 shares of the medical instruments supplier’s stock worth $1,275,000 after purchasing an additional 991 shares during the period. 96.10% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ICUI has been the subject of a number of recent research reports. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a report on Wednesday, December 11th. StockNews.com lowered ICU Medical from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Raymond James set a $97.00 target price on shares of ICU Medical in a research note on Wednesday, March 12th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $168.67.

ICU Medical Stock Down 2.9 %

NASDAQ ICUI opened at $140.16 on Monday. The stock’s 50 day simple moving average is $154.42 and its 200 day simple moving average is $163.78. ICU Medical, Inc. has a one year low of $93.36 and a one year high of $196.26. The firm has a market cap of $3.44 billion, a PE ratio of -30.67 and a beta of 0.73. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03.

Insider Transactions at ICU Medical

In related news, CEO Vivek Jain sold 1,373 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total value of $213,474.04. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.